The preclinical study evaluated the extent of absorption of lorazepam after nasal administration and the pharmacokinetics of the novel formulation. Amarin is working with a subsidiary of Elan to prepare this nasal formulation for human pharmacokinetic trials.
This nasal lorazepam formulation utilizes Elan’s proprietary NanoCrystal technology and is in development for the out-patient treatment of emergency seizures in epilepsy patients, specifically status epilepticus and acute repetitive seizures.